Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2009 Earnings Results

Alnylam Pharmaceuticals Beats on EPS, Stock Down 1.7%

Alnylam Pharmaceuticals reported a narrower loss than expected, which is a positive sign for investors. However, the stock fell by 1.7% in response to the lack of revenue details and forward guidance. Investors may be cautious as the company continues to navigate its development pipeline without clear future projections.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.19	N/A	+19.49%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management expressed a cautious optimism about their ongoing projects. They acknowledged the challenges but remain focused on long-term goals.

Management highlighted progress in their pipeline despite the loss.

They emphasized their commitment to advancing their research initiatives.

Alnylam Pharmaceuticals Beats on EPS, Stock Down 1.7%

Key numbers

Management commentary

Alnylam Pharmaceuticals, Inc.

More earnings this week

Alnylam Pharmaceuticals Beats on EPS, Stock Down 1.7%

Key numbers

Management commentary